Alteogen, a bioplatform company, announced on March 12 that it has registered a composition patent for the Keytruda subcutaneous injection product, which combines its Hybrozyme® platform-based ALT-B4 (ingredient name: berahyaluronidase alpha) with Keytruda (ingredient name: pembrolizumab), with the United States Patent and Trademark Office.


Exterior view of Alteogen headquarters and research center in Yuseong-gu, Daejeon. Alteogen

Exterior view of Alteogen headquarters and research center in Yuseong-gu, Daejeon. Alteogen

View original image

Through this patent, the subcutaneous injection formulation of Keytruda utilizing ALT-B4 (product name: Keytruda QlexTM) will be protected by the patent in the United States for approximately 17 years, until early 2043. Keytruda Qlex received FDA approval in September of last year and is currently being marketed in the United States. Alteogen is eligible to receive sales milestones totaling 1 billion dollars based on annual and cumulative sales, and after receiving all milestones, it will receive royalties based on sales revenue.


Alteogen explained that this outcome is the result of the United States Patent and Trademark Office once again confirming the novelty and originality of the invention of ALT-B4, despite intellectual property issues that had been raised regarding ALT-B4. The company added that this patent is part of its ongoing effort to strengthen the protection of the Hybrozyme® platform through a diversified portfolio. In addition to the substance patent for ALT-B4 that was registered in the United States last year, the company is supporting its partners and potential partners in developing competitive therapeutics utilizing its technology by expanding its diversified patent portfolio, providing a broader patent foundation.


Tae-Yeon Jeon, a U.S. patent attorney and CEO of Alteogen, stated, "The significance lies in securing intellectual property protection not only for the ALT-B4 substance itself, which was developed as an original invention, but also for the composition that combines it with pembrolizumab." He added, "This will support the exclusivity of Keytruda Qlex, the first product using the Hybrozyme platform."



He further commented, "From the early stages of development, Alteogen has established a comprehensive patent portfolio—including variants, compositions, and applications—by making IP a core competitive asset to ensure the stable establishment and expansion of the platform. This registration is a concrete example of that strategy yielding results."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing